• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Public Health

Methadone use for non-cancer pain associated with increased mortality

byAshley AaroeandJames Jiang
January 21, 2015
in Public Health
Reading Time: 3 mins read
Long term opioid pain therapy evidence limited, linked to serious harms
Share on FacebookShare on TwitterShare on LinkedIn

1. Methadone is an opioid analgesic often prescribed for pain management; however side effects include potentially fatal respiratory depression and ventricular arrhythmia.

2. In this study, methadone was found to be associated with increased all-cause mortality as compared to morphine sustained-release when used in non-cancer patients.

Evidence Rating Level: 2 (Good)       

Study Rundown: Methadone use has expanded beyond those receiving treatment for narcotic addiction. Due to its low cost, it is becoming a popular treatment for chronic pain. Unfortunately, this drug is characterized by variable pharmacokinetics and a long half-life, which has the potential to cause sustained respiratory depression. It can also prolong the QT interval and cause ventricular arrhythmias and sudden cardiac death. This retrospective cohort sought to investigate the effect of methadone use on all-cause mortality in patients with non-cancer pain. The investigators found that in non-cancer patients, there was an increased risk of all-cause mortality associated with methadone use as compared to morphine sustained-release (morphine SR).

This study made significant efforts to reduce and adjust for confounding factors, however more than half of the cohort also was concurrently using another drug in addition to either methadone or morphine SR. Moreover, the entire study population was comprised of Tennessee Medicaid enrollees, which could possibly limit generalizability. However, roughly one-fourth of the patients received either methadone or morphine prior to the study period, which could have eliminated patients who were more susceptible to the adverse effects. Further studies are necessary to reconcile this report with others that have found no significant increase in mortality as a result of methadone analgesic use.

Click to read the study in JAMA Internal Medicine

RELATED REPORTS

Upacicalcet reduced parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism in PATH-1 and PATH-2

WGS Oncodetect showed higher recurrence sensitivity than WES Oncodetect in colorectal cancer

Relevant Reading: Comparative mortality among Department of Veterans Affairs patients prescribed methadone or long-acting morphine for chronic pain.

In-Depth [retrospective cohort]: This study used records of 38,756 Tennessee Medicaid enrollees aged 30 to 74 years with filled prescriptions for either methadone or morphine SR between 1997 and 2009. Exclusion criteria were created in an attempt to minimize confounding from deaths related to terminal diseases such as cancer. Patients older than 75 years old and nursing home residents were also excluded, as were patients with a history of drug abuse at risk for overdose. The primary end point of the study was all deaths outside the hospital, classified into three subgroups based on death certificates: sudden unexpected deaths consistent with either opioid overdose or life-threatening arrhythmias, other cardiac or respiratory deaths for which opioid involvement was possible but not definitive, and deaths not as likely to be related to the drugs.

The most common indication for taking the study opioid was for either back or musculoskeletal pain (90%). Patients who took methadone had a 46% increased risk of death compared to morphine SR during the follow-up period of this study, with an adjusted hazard ratio of 1.46 (95%CI 1.17-1.83; p<0.001). The lowest quartile of methadone dose (<20mg/dL), when compared with an equivalent dose of morphine SR (<60 mg/dL), was also associated with an increased risk of death with an adjusted hazard ratio of 1.59 (95%CI 1.01-2.51; p=0.046). The hazard ratios calculated in this study were adjusted for covariants including patient demographics, indication for opioid treatment, psychiatric and cardiovascular conditions, and other comorbidities.

More from this author: Criminal behavior more associated with frontotemporal dementia than Alzheimer disease, “No Evidence of Disease Activity” may be useful goal in multiple sclerosis, Hyperbaric oxygen does not significantly improve post-concussion symptoms, Increased orexin levels linked with poor sleep quality in Alzheimer Disease, Antibiotic prescription patterns in China may contribute to resistance

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Previous Post

The CATT study: Avastin and Lucentis equally effective for macular degeneration [Classics Series]

Next Post

Incidental findings common with breast imaging, often benign

RelatedReports

A patient undergoing dialysis while using a pedaling device for exercise.
2MM Trial Briefs

Upacicalcet reduced parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism in PATH-1 and PATH-2

October 27, 2026
An envelope is being held with a calendar and an illustration of the colon in the background, indicating a reminder for colorectal screening.
2MM Trial Briefs

WGS Oncodetect showed higher recurrence sensitivity than WES Oncodetect in colorectal cancer

October 26, 2026
An incubator for preterm infants, alongside monitoring equipment and oxygen delivery components.
Gastroenterology

Stool biomarkers may be effective in the evaluation of necrotizing enterocolitis in preterm infants

October 26, 2026
An illustration showing human lungs, a tray with sampling devices, and a teal awareness ribbon, representing lung cancer diagnostics and lymph node sampling.
2MM Trial Briefs

Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer in interim phase 3 results

October 26, 2026
Next Post
Incidental findings common with breast imaging, often benign

Incidental findings common with breast imaging, often benign

ICU chlorhexidine baths do not reduce rates of hospital-acquired infections

ICU chlorhexidine baths do not reduce rates of hospital-acquired infections

CT may be superior to MRI for pituitary tumor detection

CT may be superior to MRI for pituitary tumor detection

✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Upacicalcet reduced parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism in PATH-1 and PATH-2
  • WGS Oncodetect showed higher recurrence sensitivity than WES Oncodetect in colorectal cancer
  • Stool biomarkers may be effective in the evaluation of necrotizing enterocolitis in preterm infants
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.